Ukraine boasts several advantages for sponsors considering the country as a location for clinical research. Its alignment with the EU and harmonization with ICH-GCP standards, high standards in education (in particular clinical and medical training), recent national programs aimed at developing a strong clinical research sector, and general economic initiatives aimed attracting international investment make Ukraine an attractive location for international sponsors.
Cromos Pharma began working in Ukraine in 2006 and established a representative office in Kyiv in 2008. Since then, our highly experienced team in Ukraine has consistently delivered exceptional results for international sponsors.
132 Holosiivskyi ave., 14-A office, Kyiv, O3127, Ukraine
With a population of over 330 million, a well-developed medical infrastructure, an ethnically diverse patient population, and the largest concentration of biotechnology and pharma companies, the United States remains the unequivocal leader and trendsetter in clinical research. Therefore, it is not surprising that half of the world’s clinical trials are conducted in the United States. In addition to the agile regulatory framework with fast initiation timelines, world-leading scientific minds, and high-quality clinical trial data, inclusion of US clinical sites is essential for drug registration with the FDA. Cromos Pharma has a strong track record of conducting clinical research in the US since 2018. Additionally, the company has a unique advantage of offering a balanced approach of including both US and ex-US clinical sites that helps accelerate recruitment and saves time and resources.
Bulgaria ranks top 20 in the world by the number of conducted clinical trials per capita and offers great potential for pharmaceutical companies and CROs alike. With around 12,000 patients enrolled annually Bulgaria is considered one of Europe’s clinical research hubs. Bulgarian Association of Clinical Research (BACR) is advocating for high standards in conducting clinical trials and for full adherence to international requirements.
Croatia provides a natural conduit between EU and non-EU countries, providing an advantage of the Croatian language which is easily understood by the non-EU countries surrounding it. Croatia has a rich heritage in terms of science and good experience in clinical research. As a result, many contract research organizations (CROs) chose Croatia to conduct clinical trials.
The Czech Republic is a well-established location for clinical trials’ conduct with a strong track record of generating high quality clinical data. In recent years, it has developed a reputation as an attractive location for niche clinical trials including hematologic malignancies, gene and cell therapies, and rare diseases. Cromos Pharma began its operations in the Czech Republic in 2010 and established a representative office in Prague in 2015.
The healthcare sector in Estonia is developing fast. The government of Estonia is constantly working to improve the clinical research environment in the country. The number of study centers has grown and the annual number of submitted clinical trial protocols have steadily increased over the last two decades.
Georgia offers international sponsors significant benefits that include a rapid regulatory approval process, substantial naïve patient populations in a wide range of therapeutic indications, skilled medical personnel, and a conducive economic environment for doing business. Cromos Pharma began conducting clinical research in Georgia in 2013. Since then, our Tbilisi-based operation has grown exponentially, managing numerous successful regional and global studies in a broad range of therapeutic indications.
Hungary boasts several key advantages for sponsors considering this country as a destination for their clinical research. Its membership in the EU, high educational standards, recent launch of national programs aimed at developing a strong medical research sector, and general economic initiatives aimed at attracting international investment all position Hungary as an attractive location. Each year approximately 20,000 Hungarian patients participate in clinical trials. Cromos Pharma established its office in Budapest in 2016.
There are many benefits to conducting clinical research in Kazakhstan, its strategic geography being one of them. Kazakhstan is a transcontinental country located between Europe and Central Asia, and its health demographics draw influence from both continents. This is one reason why an increasing number of biopharmaceutical companies are considering Kazakhstan as a venue for conducting clinical research. Cromos Pharma began operations in Kazakhstan in 2017, where it initially conducted phase 3 oncology trials, but since has broadened its scope of services. The company opened a regional office in Almaty in 2021.
There has been a stable increase in clinical trials in Latvia over the last 10 years. GCP trainings are well organized by the Medicine Information Centre and all participating investigators are GCP-trained. Following the European Union accession, Latvia has implemented EU directives 2001/20 and 2005/28, and incorporated GCP guidelines into the national law.
Lithuania offers companies a business model favorable to the conduct of clinical research, which is increasingly recognized by many key players in the sector. To date, more than 90 international biotech and pharma companies, including global players, have chosen Lithuania as a location to conduct their clinical trials.
For a relatively small country the number of clinical trials in Moldova is growing rapidly. All clinical trial sites comply with the national and ICH/GCP standards. Moldova offers fast and effective recruitment and a large pool of a treatment-naïve population.
With excellent patient recruitment, an established framework for conducting clinical trials, a large population of skilled clinical professionals and a reputation for producing high quality data, Poland remains a key location for international biopharmaceutical sponsor companies. Cromos Pharma has been conducting clinical research in Poland since 2015 and opened a permanent office in Warsaw in early in 2020.
Romania has a population of 19.4 million people, which ensures high patient availability. The overall data quality provided by the investigational sites is very high and comparable with that of Western Europe, whereas the monitoring costs and the investigator fees are considerably lower. As the country’s healthcare sector is rapidly growing, more and more sponsors are including Romania in its clinical programs.
Over the years, Serbia has become a highly reputable location to conduct clinical research. The country has actively strived towards developing a robust healthcare system and has adopted full GCP compliance. An increasing number of biotechnology and pharmaceutical companies are now willing to envision Serbia as a potential regional hub for their business operations and thus are making significant investments in the Serbian market.
The Slovak Republic’s health system has clear advantages for clinical trials conduct. The state is fully compliant with EU directives and conducts clinical trials in accordance with EMA’s regulations. The country’s centralized healthcare system allows for seamless management and communication and the cost of clinical trials is significantly lower than in Western Europe.
Slovenia traditionally has a short start-up period, so it is a beneficial landscape to speed up patient recruitment. Slovenia has a network of public and private healthcare providers, research sites in the country are well-equipped and the medical staff is highly motivated. European Union directives are incorporated into Slovenian legislation.
With a population of over 85 million, a well-developed universal healthcare system, a relatively low per capita number of clinical trials, and a large pool of treatment-naive patients, Türkiye is a hidden gem in clinical research. In fact, the number of biotech and pharma companies that are getting engaged in Türkiye has been on the rise, with the number of clinical trials doubling there for the last 3 years. Over the past two decades the country has steadily worked its way to establishing a strong reputation in the clinical trials segment. Today, these efforts are coming to fruition, as evidenced by the rising number of international companies looking at Türkiye for their next trials.
Ukraine boasts several advantages for sponsors considering the country as a location for clinical research. Its alignment with the EU and harmonization with ICH-GCP standards, high standards in education (in particular clinical and medical training), recent national programs aimed at developing a strong clinical research sector, and general economic initiatives aimed attracting international investment make Ukraine an attractive location for international sponsors. Cromos Pharma began working in Ukraine in 2006 and established a representative office in Kyiv in 2008. Since then, our highly experienced team in Ukraine has consistently delivered exceptional results for international sponsors.